Molecular Health appoints Christian Meisel, MD, PhD, as Chief Medical Officer | Molecular Health

Newsroom

All news

Molecular Health appoints Christian Meisel, MD, PhD, as Chief Medical Officer

Heidelberg, Germany – Tuesday, May 7, 2019–Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of products and services leveraging its proprietary biomedicine technology platform Dataome, today announced the appointment ofDr. Christian Meisel as corporate Chief Medical Officer (CMO).

 

Dr. Meiselcomes to Molecular Health with over 25years of experience in the healthcare sector–including clinical practiceand research &development across academia and the biopharmaceutical industry–andmore than 10 years in senior pharma leadership roles. As anMDandPhD with additional qualifications in computer science and extensive experience in precision medicine, Dr. Meisel will be responsible for all clinical aspectsof Molecular Health’sportfolioand development. As a member of the company’s leadership,he will also provide strategicdirection and leadership in the development of Molecular Health.

 

Dr. Friedrich von Bohlen, Co-founder and CEO of Molecular Health, said:”Weare very pleasedto have Dr. Meisel join as our Chief Medical Officer. He not only is anexperiencedphysician but, next to his background in computer science, also brings an extensivetrack record and expertise in precision medicineacross the biopharmaceutical and diagnostics industry. With his broadexperience in molecular diagnostics and drug development,he is a perfect addition to our development and commercial teams and willstrategically enhanceand further sharpen thefocus of our offerings to pharma, physicians, providers, payersand the financial industry. The CMO position is key for our growth strategy, and we are happy to havefound Christianfor this important role at Molecular Health.”

 

Dr. Meisel adds: “I am very much looking forwardto joiningMolecular Health –a company at the forefront of the digital transformation of medicine and R&D –as a member of the executive team. I will bring my first-hand experience and deep knowledge of the demandsof patients and healthcare providers to further improveMolecular Health’s innovative solutions to impact patient care,therapeutic and diagnostic product development,and meet the growing needs of the medical community in the digitalization of healthcare.”

 

Dr. Christian Meisel joins Molecular Health from Roche where heserved for more than 14 years in numerous senior leadership roles, including Global Head Personalized Healthcare Platform, acting Global Head Translational Medicine Oncology, and Global Head Biomarkers and Translational R&D Innovation. Dr. Meisel is board-certified in Internal Medicine and in Clinical Pharmacology, holds an MD from the Technical University of Munich, and a PhD from Charité Berlin, where he also served as associate professor and leader of a bioinformatics research group.

 

About Molecular Health

Molecular Health is a data science-focused artificial intelligencecomputing company enabling and improving decision making in precision medicine for healthcare organizations.The company offerings are based on the capture, curation, integration, and analysis of large biomedical and drug data sets andcombining them with novel artificial intelligence and machine learning (AI/ML) technologies.For more than a decade, the company has been developingDataome, a unique high-quality curated, interoperable system that combines clinico-molecular and drug data with proprietary analytical processes.Dataome –stand alone or in combination with customer data –enables the unlocking of actionable intelligence at the molecular level toa)improve diagnosis and therapy decisions by physicians and patients;b) enrich and support better drug discovery, drug development, trial optimization, drug differentiation and positioning for pharma and healthcare organizations;andc) more accurately predict the likelihood of success and likelihood of approval of drug candidates in clinical development for better trial prioritization and resource and investment allocation.For more information,visit www.molecularhealth.com.

 

Molecular Health GmbH
Thomas König
Head of Marketing
thomas.koenig@molecularhealth.com

 

Media Relations
MC Services AG
Katja Arnold, Eva Bauer, Laurie Doyle
molecularhealth@mc-services.eu
+49-89-210 2280